Blog Posts

HRSA Tells UCB its 340B Contract Pharmacy Policy Is Illegal

HRSA told drug manufacturer UCB yesterday its conditions on 340B pricing when hospitals use contract pharmacies are illegal and must stop or the company could face civil monetary penalties.

Federal healthcare officials told drug manufacturer UCB yesterday its restrictions on 340B pricing when covered entities use contract pharmacies are illegal and must stop or the company could face civil monetary penalties of up to $6,323.00 for each

Read More »

Feds Ask Appeals Court to Partially Reverse Ruling on Lilly’s 340B Contract Pharmacy Policy

The federal government asked an appeals court to affirm one part and vacate another of a lower court's opinion about the legality of Lilly's 340B contract pharmacy restrictions.

A federal district judge was right to decide that drug manufacturer Lilly cannot tie strings to 340B pricing on its drugs, the U.S. Justice Department told a federal appeals court in Chicago on Friday.

Please Login

Read More »

Meet AIDS Healthcare Foundation Pharmacist, and Artist, Alsean Bryant

SPONSORED CONTENT

The 340B drug pricing program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. But 340B’s benefit goes beyond providing office visits with a physician and prescriptions to control HIV. 340B also supports the execution of many pharmacy support services. One is AIDS Healthcare Foundation’s Strategic Response Team (SRT). 

Alsean Bryant, an AHF pharmacist

Read More »

Clinics Pay Gilead $33 Million to Settle Fraud Claims Involving 340B-Related PrEP Transactions

A group of Florida healthcare providers will pay $33 million to settle Gilead's claims the group made fraudulent 340B-related transactions involving the company’s HIV pre-exposure prophylaxis drugs.

One of two groups of Florida health care providers that drug maker Gilead accused of making fraudulent 340B-related transactions involving the company’s HIV pre-exposure prophylaxis drugs agreed last week to settle Gilead’s claims against it for $33 million.

Read More »

Supreme Court DSH Calculation Ruling Leaves 340B Status Quo in Place, Experts Say

A U.S. Supreme Court decision about the Medicare DSH adjustment percentage calculation is expected to have little effect on hospitals currently in the 340B drug pricing program.

A U.S. Supreme Court decision last week about the Medicare disproportionate share adjustment percentage calculation will have little effect on hospitals currently in the 340B drug pricing program, experts say.

Please Login or Become a Paid

Read More »

340B Report Publisher and CEO: Takeaways from Supreme Court’s Part B Cuts Decision

The U.S. Supreme Court opinion striking down huge cuts in 340B hospitals’ Medicare Part B drug reimbursement “is a clear and much welcome victory" for the hospitals, 340B Report Publisher and CEO Ted Slafsky says.

The U.S. Supreme Court’s unanimous June 15 ruling that huge cuts in 340B hospitals’ Medicare Part B drug reimbursement were unlawful “is a clear and much welcome victory for 340B hospitals,” 340B Report Publisher and CEO Ted Slafsky

Read More »

How to Handle Increased Manufacturer Inquiries…From Manufacturers With Extraordinary Price Increases

SPONSORED CONTENT

So you’ve received a “good faith” inquiry from a manufacturer questioning your purchases and utilization. You have run the numbers and don’t see anything that indicates an issue. It may seem like it’s out of the blue because these products may have low overall spend or low volume and may not hit your internal markers for audit flags.  340B

Read More »

White House Now Says This Is Target Month for New 340B ADR Rule, but Publication Date Remains a Mystery

The White House says this is the target month to release a long delayed proposed rule to replace the existing 340B ADR final rule. But it is unclear whether it will be delayed again.

The White House now says that this is the target month for releasing a long delayed proposed rule to replace 340B program dispute resolution regulations.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Bill Would Give HIV/AIDS Clinics More Leeway to Use 340B Savings and Other Program Income

A bill has been introduced in Congress that would get rid of a major barrier that prevents Ryan White clinics from providing PrEP to those at high risk of contracting the HIV/AIDS virus.

U.S. Sens. Rick Scott (R-Fla.) and Ben Ray Luján (D-N.M.) have introduced a bill to let Ryan White clinics use income from being in the HIV/AIDS program to provide pre-exposure prophylaxis, or PrEP, a daily medication used to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report